Xbrane Biopharma AB (STU:7XB) Total Assets : €79.41 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Xbrane Biopharma AB Total Assets?

Xbrane Biopharma AB's Total Assets for the quarter that ended in Mar. 2024 was €79.41 Mil.

Warning Sign:

If a company builds assets at 34.9% a year, faster than its revenue growth rate of 24.8% over the past 5 years, it means that the company may be getting less efficient.

During the past 12 months, Xbrane Biopharma AB's average Total Assets Growth Rate was 18.20% per year. During the past 3 years, the average Total Assets Growth Rate was 38.70% per year. During the past 5 years, the average Total Assets Growth Rate was 34.90% per year. During the past 10 years, the average Total Assets Growth Rate was 93.50% per year.

During the past 11 years, Xbrane Biopharma AB's highest 3-Year average Total Assets Growth Rate was 564.60%. The lowest was 23.20%. And the median was 38.00%.

Total Assets is connected with ROA %. Xbrane Biopharma AB's annualized ROA % for the quarter that ended in Mar. 2024 was -49.96%. Total Assets is also linked to Revenue through Asset Turnover. Xbrane Biopharma AB's Asset Turnover for the quarter that ended in Mar. 2024 was 0.02.

Xbrane Biopharma AB Total Assets Historical Data

The historical data trend for Xbrane Biopharma AB's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xbrane Biopharma AB Total Assets Chart

Xbrane Biopharma AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Assets

Get a 7-Day Free Trial

32.34

45.58

67.03

62.81

58.42

Xbrane Biopharma AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Assets	Get a 7-Day Free Trial															58.03	85.60	75.30	58.42	79.41

Xbrane Biopharma AB Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Xbrane Biopharma AB's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (A: Dec. 2023 )	+	Total Liabilities (A: Dec. 2023 )
	=	15.317	+	43.105
	=	58.42

Xbrane Biopharma AB's Total Assets for the quarter that ended in Mar. 2024 is calculated as

Total Assets	=	Total Equity (Q: Mar. 2024 )	+	Total Liabilities (Q: Mar. 2024 )
	=	34.827	+	44.583
	=	79.41

Xbrane Biopharma AB (STU:7XB) Total Assets Explanation

Total Assets is connected with ROA %.

Xbrane Biopharma AB's annualized ROA % for the quarter that ended in Mar. 2024 is

ROA %	=	Net Income (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
	=	-34.428	/	( (58.422	+	79.41)	/ 2 )
	=	-34.428	/	68.916
	=	-49.96 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Xbrane Biopharma AB's Asset Turnover for the quarter that ended in Mar. 2024 is

	Asset Turnover
=	Revenue (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
=	1.246	/	( (58.422	+	79.41)	/ 2 )
=	1.246	/	68.916
=	0.02

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Xbrane Biopharma AB Total Assets Related Terms

Thank you for viewing the detailed overview of Xbrane Biopharma AB's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Xbrane Biopharma AB (STU:7XB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xbrane Biopharma AB (STU:7XB) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

XBRANE:Sweden 7XB:Germany

Address

Retzius vag 8, Solna, SWE, 171 65

Website

https://www.xbrane.com

Xbrane Biopharma AB is a biotechnology company that develops biosimilars. The company has a patented protein production platform with up to 12 times greater productivity than standard systems for the production of proteins in E.coli host cells. Xbrane's leading product candidate is Ximluci, a ranibizumab biosimilar (original drug Lucentis) used in the treatment of various eye diseases, mainly the wet form of age-related macular degeneration. The company's geographical segments include the Middle East, Asia, Europe, and the United States.

Xbrane Biopharma AB (STU:7XB) Headlines

No Headlines